Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
US10532099B2 · kind B2 · utility
4Cited by
15References
67Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2017 |
| Grant date | Jan 14, 2020 |
| Priority date | — |
| Expiry date | Oct 18, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.